| Literature DB >> 34921324 |
Thomas Möller1, Vibeke Klungerbo2,3, Simone Diab2,3, Henrik Holmstrøm2,3, Elisabeth Edvardsen4,5, Guro Grindheim6, Henrik Brun2, Erik Thaulow2, Alvaro Köhn-Luque7, Assami Rösner8, Gaute Døhlen2.
Abstract
The role of dysfunction of the single ventricle in Fontan failure is incompletely understood. We aimed to evaluate hemodynamic responses to preload increase in Fontan circulation, to determine whether circulatory limitations in different locations identified by experimental preload increase are associated with cardiorespiratory fitness (CRF), and to assess the impact of left versus right ventricular morphology. In 38 consecutive patients (median age = 16.6 years, 16 females), heart catheterization was supplemented with a rapid 5-mL/kg body weight volume expansion. Central venous pressure (CVP), ventricular end-diastolic pressure (VEDP), and peak systolic pressure were averaged for 15‒30 s, 45‒120 s, and 4‒6 min (steady state), respectively. CRF was assessed by peak oxygen consumption (VO2peak) and ventilatory threshold (VT). Median CVP increased from 13 mmHg at baseline to 14.5 mmHg (p < 0.001) at steady state. CVP increased by more than 20% in eight patients. Median VEDP increased from 10 mmHg at baseline to 11.5 mmHg (p < 0.001). Ten patients had elevated VEDP at steady state, and in 21, VEDP increased more than 20%. The transpulmonary pressure difference (CVP‒VEDP) and CVP were consistently higher in patients with right ventricular morphology across repeated measurements. CVP at any stage was associated with VO2peak and VT. VEDP after volume expansion was associated with VT. Preload challenge demonstrates the limitations beyond baseline measurements. Elevation of both CVP and VEDP are associated with impaired CRF. Transpulmonary flow limitation was more pronounced in right ventricular morphology. Ventricular dysfunction may contribute to functional impairment after Fontan operation in young adulthood.ClinicalTrials.gov identifier NCT02378857.Entities:
Keywords: Fontan circulation; Hemodynamics; Preload challenge; Transpulmonary gradient; Univentricular congenital heart defects; Ventricular function
Mesh:
Year: 2021 PMID: 34921324 PMCID: PMC9005395 DOI: 10.1007/s00246-021-02802-y
Source DB: PubMed Journal: Pediatr Cardiol ISSN: 0172-0643 Impact factor: 1.655
Fig. 1Flowchart of patient enrollment in the present study. CPET cardiopulmonary exercise test, HC heart catheterization, HT heart transplantation
General characteristics of the study population with heart catheterization and preload challenge (n = 38)
| Variable | Value | % |
|---|---|---|
| Median age [years] | 16.6. (15.4–17.9) | |
| Sex [female/male] | 16/22 | 42/58 |
| Median body mass index [kg/m2] | 20.9 (15.3–31.0) | |
| Median oxygen saturation at rest [%] | 95 (91–98) | |
| Median age at Fontan operation [years] | 2.0 (1.0–11.0) | |
| Median elapsed time since Fontan operation [years] | 14.4 (6.0–16.7) | |
| Fontan-type (extra-cardiac/lateral tunnel) | 28/10 | 74/26 |
| Systemic ventricular morphology (LV/RV/common) | 19/16/3 | 50/42/8 |
| Atrioventricular valve regurgitation (none/mild/moderate) | 11/22/5 | 29/58/13 |
| Open fenestration | 1 | |
| Protein-losing enteropathy (by clinical judgment) | 4 | 11 |
| Hypoplastic left heart syndrome | 10 | 26 |
| Tricuspid atresia | 8 | 21 |
| Double outlet right ventricle | 4 | 11 |
| Double inlet left ventricle | 4 | 11 |
| Pulmonary atresia/intact ventricular septum | 3 | 8 |
| Other (unbalanced AVSD, hypoplastic right ventricle, etc.) | 9 | 23 |
| Heterotaxy syndrome | 1 | 3 |
| Pacemaker | 6 | 16 |
| ICD | 0 | |
| Acetylsalicylic acid | 26 | 68 |
| Warfarin | 10 | 26 |
| Angiotensin-converting enzyme inhibitor | 6 | 16 |
| Pulmonary vasodilator (sildenafil and/or bosentan) | 4 | 11 |
| Diuretics (furosemide and/or hydrochlorothiazide) | 5 | 13 |
| Aldosterone antagonist | 3 | 8 |
| Beta-blocker | 2 | 5 |
| Antiarrhythmic drugs (non-beta-blocker) | 0 |
LV/RV left/right ventricular morphology, AVSD atrioventricular septal defect, ICD implantable cardioverter-defibrillator
Values are counts (n) unless otherwise specified
Hemodynamic parameters at baseline and after rapid volume expansion (RVE)
| Heart rate (non-pacemaker patients) [beats per minute] | All ( | LV ( | RV ( | Self-breathing | General anesthesia | |
|---|---|---|---|---|---|---|
| Baseline | 75.5 ± 15.3 | 73.9 ± 16.8 | 75.7 ± 15.4 | 69.8 ± 16.1 | 79.0 ± 13.7 | |
| Lowest during the 1st minute after RVE | 65.9 ± 13.8 | < 0.001 | 62.5 ± 12.8 | 68.2 ± 15.8 | 61.9 ± 13.5 | 68.6 ± 13.4 |
| Steady state | 72.4 ± 14.2 | < 0.001 | 68.7 ± 14.8 | 74.2 ± 14.5 | 66.9 ± 14.8 | 75.9 ± 12.5 |
LV/RV left/right ventricular morphology, CVP central venous pressure, s seconds, VEDP ventricular end-diastolic pressure
Normal distribution of data confirmed with the Shapiro–Wilk test unless marked by *. Comparisons performed as appropriate with paired/non-paired Student’s t-test, related samples Wilcoxon signed rank test, or Mann–Whitney U test
Fig. 2Heart rate response to rapid volume expansion (RVE) in non-pacemaker patients (N = 31)
Fig. 3Central venous pressure before and after rapid volume expansion (RVE)
Fig. 4Ventricular end-diastolic pressure before and after rapid volume expansion (RVE). Central illustration: Rapid volume expansion by intravenous saline bolus unmasks limitations of the Fontan circulation by pressure rise upstream from the blood flow restriction(s)
Results from the cardiopulmonary exercise testing
| N | All | LV ( | RV ( | ||
|---|---|---|---|---|---|
| VO2peak [mL × kg−1 × min−1] | 36 | 31.6 ± 7.6 | 32.9 ± 7.0 | 29.6 ± 7.9 | 0.354* |
| VO2peak [percent of predicted] | 36 | 59 ± 13 | 62 ± 13 | 55 ± 12 | 0.087 |
| VO2 at VT [mL × kg−1 × min−1] | 35 | 21.6 ± 4.6 | 22.5 ± 3.8 | 20.8 ± 5.4 | 0.302 |
| VO2 at VT [% of VO2peak] | 35 | 70 ± 8.7 | 70 ± 8.6 | 71 ± 9.0 | 0.746 |
| VO2 at VT [% of predicted] | 35 | 44 ± 7.9 | 43 ± 7.0 | 39 ± 8.7 | 0.116 |
VO2 oxygen consumption, VO2peak peak oxygen consumption, VT ventilatory threshold, LV/RV left/right ventricular morphology
*Mann–Whitney U test, other non-paired two-tailed Student’s t-test
Associations of hemodynamic variables with cardiorespiratory fitness by linear regression analysis
| Pressure readings at baseline and after RVE | VO2peak | VO2@VT | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Univariate | |||||||
| 95% CI | 95% CI | |||||||
| CVP baseline | − 0.84 | − 1.56 to − 0.12 | 0.143 | 0.023 | 1.67 | 0.72‒2.65 | 0.277 | 0.001 |
| CVP 45‒120 s (average) | − 0.99 | − 1.75 to − 0.22 | 0.169 | 0.013 | 1.80 | 0.83‒2.77 | 0.302 | 0.001 |
| CVP maximum | − 0.90 | − 1.61 to − 0.19 | 0.162 | 0.015 | 1.72 | 0.85‒2.58 | 0.332 | < 0.001 |
| CVP at 4‒6 min (average) | − 0.99 | − 1.78 to − 0.20 | 0.161 | 0.015 | 1.68 | 0.69‒2.66 | 0.267 | 0.001 |
| VEDP baseline | 0.26 | 1.03 | 0.23‒1.83 | 0.173 | 0.013 | |||
| VEDP 45‒120 s (average) | 0.508 | 0.96 | 0.15‒1.77 | 0.15 | 0.022 | |||
| VEDP maximum | 0.48 | 0.77 | 0.03‒1.52 | 0.119 | 0.043 | |||
| VEDP at 4‒6 min (average) | 0.368 | 0.90 | 0.06‒1.74 | 0.127 | 0.036 | |||
| CVP‒VEDP baseline | 0.51 | 0.953 | ||||||
| CVP‒VEDP 45‒120 s (average) | 0.144 | 0.844 | ||||||
| CVP–VEDP maximum | 0.189 | 0.909 | ||||||
| CVP‒VEDP at 4‒6 min (average) | 0.362 | 0.848 | ||||||
CVP central venous pressure, min minutes, VEDP ventricular end-diastolic pressure, RVE rapid volume expansion, s seconds, VO peak oxygen consumption, VO@VT ventilatory threshold at VO2peak